MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

Search

Abbott Laboratories

Suletud

SektorTervishoid

128.47 1.01

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

128.47

Max

129.22

Põhinäitajad

By Trading Economics

Sissetulek

454M

1.8B

Müük

784M

11B

P/E

Sektori keskmine

16.484

36.442

Aktsiakasum

1.26

Dividenditootlus

1.75

Kasumimarginaal

15.967

Töötajad

114,000

EBITDA

383M

3B

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+14.07% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

1.75%

3.00%

Järgmine dividendimakse kuupäev

17. nov 2025

Turustatistika

By TradingEconomics

Turukapital

-1B

229B

Eelmine avamishind

127.46

Eelmine sulgemishind

128.47

Uudiste sentiment

By Acuity

57%

43%

296 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Abbott Laboratories Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

15. okt 2025, 12:02 UTC

Tulu

Abbott Labs Posts Higher 3Q Sales, Reaffirms Outlook

17. juuli 2025, 12:10 UTC

Tulu

Abbott Labs Pares Outlook, Logs 2Q Profit Gains

15. okt 2025, 16:15 UTC

Tulu

Abbott Stock Drops Despite Earnings. Baby-Formula Sales Took a Hit. -- Barrons.com

15. okt 2025, 12:25 UTC

Tulu

Abbott Posts Solid Earnings, Adult Nutrition Drives Sales. The Stock Drops Anyway. -- Barrons.com

15. okt 2025, 11:32 UTC

Tulu

Abbott Labs Still Sees 2025 Organic Sales Up 6%-7% Including Covid-19 Testing-Related Sales >ABT

15. okt 2025, 11:32 UTC

Tulu

Abbott Labs Still Sees 2025 Organic Sales Up 7.5%-8% Excluding Covid-19 Testing-Related Sales >ABT

15. okt 2025, 11:31 UTC

Tulu

Abbott Labs Sees 2025 Adj EPS $5.12-Adj EPS $5.18 >ABT

15. okt 2025, 11:30 UTC

Tulu

Abbott Labs 3Q Adjusted Operating Margin 23% >ABT

15. okt 2025, 11:30 UTC

Tulu

Abbott Labs Reaffirms Full-Year Guidance >ABT

15. okt 2025, 11:30 UTC

Tulu

Abbott Labs 3Q Organic Sales Growth Up 5.5% >ABT

15. okt 2025, 11:30 UTC

Tulu

Abbott Labs 3Q Sales $11.37B >ABT

15. okt 2025, 11:30 UTC

Tulu

Abbott Labs 3Q Adj EPS $1.30 >ABT

15. okt 2025, 11:30 UTC

Tulu

Abbott Labs 3Q Net $1.64B >ABT

15. okt 2025, 11:30 UTC

Tulu

Abbott Labs 3Q EPS 94c >ABT

11. okt 2025, 00:18 UTC

Omandamised, ülevõtmised, äriostud

Why Biotech May Be Back -- Barrons.com

17. juuli 2025, 13:14 UTC

Tulu

Abbott Labs Stock Falls After Earnings. Why Rising Sales Fail to Lift Shares. -- Barrons.com

17. juuli 2025, 12:16 UTC

Tulu

Abbott Labs Stock Dives After Earnings Miss. Why Rising Sales Fail to Lift Shares. -- Barrons.com

17. juuli 2025, 11:32 UTC

Tulu

Abbott Labs Sees 3Q Adj EPS $1.28-Adj EPS $1.32 >ABT

17. juuli 2025, 11:32 UTC

Tulu

Abbott Labs: See Momentum Carrying Into 2026 >ABT

17. juuli 2025, 11:31 UTC

Tulu

Abbott Labs Sees 2025 Organic Sales Up 7.5%-8%, Excluding Covid-19 Testing-Related Sales >ABT

17. juuli 2025, 11:30 UTC

Tulu

Abbott Labs 2Q Organic Sales Rose 6.9% >ABT

17. juuli 2025, 11:30 UTC

Tulu

Abbott Labs 2Q Adjusted Operating Margin 22.9% >ABT

17. juuli 2025, 11:30 UTC

Tulu

Abbott Labs 2Q Adjusted Gross Margin 57% >ABT

17. juuli 2025, 11:30 UTC

Tulu

Abbott Labs 2Q Organic Sales Growth Up 6.9% >ABT

17. juuli 2025, 11:30 UTC

Tulu

Abbott Labs 2Q Sales $11.14B >ABT

17. juuli 2025, 11:30 UTC

Tulu

Abbott Labs 2Q Net $1.78B >ABT

17. juuli 2025, 11:30 UTC

Tulu

Abbott Labs 2Q Adj EPS $1.26 >ABT

17. juuli 2025, 11:30 UTC

Tulu

Abbott Labs Sees FY Adj EPS $5.10-Adj EPS $5.20 >ABT

17. juuli 2025, 11:30 UTC

Tulu

Abbott Labs 2Q EPS $1.01 >ABT

17. juuli 2025, 09:08 UTC

Kuumad aktsiad

Stocks to Watch Thursday: TSMC, United Airlines, Sarepta -- WSJ

Võrdlus sarnastega

Hinnamuutus

Abbott Laboratories Prognoos

Hinnasiht

By TipRanks

14.07% tõus

12 kuu keskmine prognoos

Keskmine 146.63 USD  14.07%

Kõrge 162 USD

Madal 136 USD

Põhineb 20 Wall Streeti analüütiku instrumendi Abbott Laboratories 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

20 ratings

18

Osta

2

Hoia

0

Müü

Tehniline skoor

By Trading Central

132.82 / 134.43Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Neutral Evidence

Pikk perspektiiv

Bullish Evidence

Sentiment

By Acuity

296 / 371 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
help-icon Live chat